Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shannon R. Morris"'
Autor:
Shannon R. Morris, Azeem Saleem, Ademi Santiago-Walker, Sam J. Madison, Nona Rama, Cristian Salinas, Roberto Dina, Sarah P. Blagden, Hatice Gungor, Hani Gabra, Mona El-Bahrawy, Edward Curry, Roshan Agarwal, Michele Chen, Deborah A. Smith, Sabin Carme, Euan A. Stronach, Emily Pickford, Elizabeth C. Krachey, Syed Babar
AKT (a serine/threonine-specific protein kinase) regulates many cellular processes contributing to cytotoxic drug resistance. This study’s primary objective examined the relationship between GSK2141795, an oral, pan-AKT inhibitor, and 18F-FDG PET m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18310a199ad5d7fa6cd893fc9ec3c92b
http://hdl.handle.net/10044/1/44102
http://hdl.handle.net/10044/1/44102
Autor:
Thomas A. Lampkin, Emily K. Bergsland, Deborah A. Smith, Neeraj Agarwal, Razelle Kurzrock, Ruud van der Noll, Petronella O. Witteveen, Michael Durante, Joseph F. Kleha, Laurel M. Adams, Shannon R. Morris, Rahul Aggarwal, David S. Hong, Pamela N. Munster, E. Claire Dees, Jennifer M. Specht, Theresa L. Werner, Jan H.M. Schellens
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(8)
Purpose: GSK2126458 (GSK458) is a potent inhibitor of PI3K (α, β, γ, and δ), with preclinical studies demonstrating broad antitumor activity. We performed a first-in-human phase I study in patients with advanced solid tumors. Materials and Method
Autor:
S. Gail Eckhardt, Gerald S. Falchook, Razelle Kurzrock, Carlos Becerra, Howard A. Burris, Keith T. Flaherty, Ngocdiep T. Le, Douglas J. DeMarini, Donna S. Cox, Vijay Gopal Reddy Peddareddigari, Sujatha Nallapareddy, Wells A. Messersmith, Leslie A. Fecher, Michael S. Gordon, Shannon R. Morris, Jeffrey R. Infante, Johanna C. Bendell, Yanmei Xu, Lowell L. Hart
Publikováno v:
The Lancet. Oncology. 13(8)
Summary Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 inhibitor. We aimed to define the maximum tolerated dose
Autor:
Thomas A. Lampkin, J.H.M. Schellens, Adil Daud, Elizabeth Claire Dees, Jennifer M. Specht, E. Y. Yu, E. E. Voest, Gerald Steven Falchook, Martijn P. Lolkema, Emily K. Bergsland, Shannon R. Morris, R. Kurzrock, Deborah A. Smith, Juneko E. Grilley-Olson, Sheng-Bin Peng, Siquing Fu, Joseph F. Kleha, Antoinette R. Tan, Pamela N. Munster, R. van der Noll
Publikováno v:
Journal of Clinical Oncology. 29:3018-3018
3018 Background: Phosphatidylinositol 3-kinase (PI3K) is critical to cancer cell growth, survival, and metabolism. GSK458 is an oral, potent inhibitor of PI3K (α, β, γ, δ), mTORC1, and mTORC2. Preclinically, GSK458 has demonstrated broad anti-tum
Autor:
A. Santiago-Walker, Azeem Saleem, Emily Pickford, Sarah P. Blagden, Roger N. Gunn, Yvonne Lewis, E. Krachey, Roshan Agarwal, Hani Gabra, M. Chen, S. C. Carme, Hatice Gungor, Deborah A. Smith, Mona El-Bahrawy, Euan A. Stronach, S. A. Babar, Shannon R. Morris, Nona Rama, Cristian Salinas, Agnieszka Michael
Publikováno v:
Journal of Clinical Oncology. 29:5064-5064
5064 Background: GSK795 is a potent, ATP-competitive, pan AKT inhibitor. The purpose of this study was to characterize the relationship between AKT inhibition by GSK795 and downstream effects in platinum resistant ovarian cancer pts. Methods: Pts wit
Autor:
Wells A. Messersmith, P. G. Kaminker, H. A. Burris, Branimir I. Sikic, Shannon R. Morris, D.R. Camidge, Hua Li, Heather A. Wakelee, J. R. Infante, G. Gallant, S. G. Eckhardt, A.D. Colevas, Suzanne F. Jones
Publikováno v:
Journal of Clinical Oncology. 29:3008-3008
3008 Background: IAPs are key regulators of cancer cell survival, which makes them appealing targets for cancer therapy. HGS1029 is a small molecule IAP inhibitor which directly kills tumor cells as a single-agent or in combination. Methods: The safe
Autor:
Deborah A. Smith, Joyce M Antal, L.L. Siu, Philippe L. Bedard, J. L. Gauvin, R. Kurzrock, Laurel M. Adams, T. Gonzalez, H. A. Burris, J. R. Infante, Joanna Opalinska, Kathleen N. Moore, Jennifer J. Wheler, Carla Kurkjian, Shannon R. Morris, Carol Aghajanian, J. F. Gerecitano
Publikováno v:
Journal of Clinical Oncology. 29:3003-3003
3003 Background: GSK795 is a potent pan-isoform inhibitor of AKT. The objectives were to define the maximum tolerated dose (MTD), and to evaluate the PK, PD and clinical activity of GSK795 in patients (pts) with advanced solid tumors. Methods: GSK795
Autor:
Donna S. Cox, Wells A. Messersmith, Leslie A. Fecher, H. A. Burris, Sujatha Nallapareddy, Keith T. Flaherty, J. R. Infante, Douglas J Demarini, Shannon R. Morris, Michael S. Gordon
Publikováno v:
Journal of Clinical Oncology. 28:2503-2503
2503 Background: GSK1120212 is a potent and selective allosteric inhibitor of MEK1/2. The objectives of this study are to define the maximum tolerated dose (MTD), and to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and response rate of